New Retina Radio
New Retina Radio

07.07.25

GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion. 

View full description +

MORE EPISODES

10.01.26

The Fellow Eye: Episode 7

Justin C. Muste, MD; David Fell, MD; Matthew Starr, MD; and Timothy Xu, MD

09.24.26

Spotlight on UNITY® VCS: 50 Cases In

Matthew Cunningham, MD, FASRS and Steven Yeh, MD, FASRS

09.18.26

Vitreous Hemorrhage Following PVD: Who Needs Surgery?

Barton Blackorby, MD, Matt Starr, MD, and Kyle Kovacs, MD

09.10.26

Spotlight on UNITY® VCS: Breaking New Ground

Jay Sridhar, MD; and Nina Berrocal, MD

08.27.26

ASRS '26: ArMaDa/GARDian Results and Real-World YAG Complication Incidence

Jay Chhablani, MD; and Jordan Deaner, MD

08.20.26

Comparing Ocular AEs in Next-Gen Treatments

Katherine Talcott, MD; Akshay Thomas, MD; and Nita Valikodath, MD, MS

08.18.26

The Story Behind LYTENAVA™: From FDA Approval to Retina Practice

Barry Kuppermann, MD, PhD; and Bob Jahr, CEO of Outlook Therapeutics

08.12.26

The Fellow Eye: Episode 6

Justin C. Muste, MD; David Fell, MD; Monia Reding, MD; and Benjamin Young, MD

Show More